Astellas And Effector Cell Institute To Jointly Develop Autoimmune Drug
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma has signed a licensing deal with Tokyo-based Effector Cell Institute to develop a new drug based on the novel target protein FROUNT in the area of autoimmune disorders, such as transplant rejection and rheumatoid arthritis. Under the license, Effector will receive an up-front payment and research fees, as well as development milestones related to the compound. (Click for more-Japanese language